Drugs Made in America Acquisition Ii CORP S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Drugs Made In America Acquisition II Corp., a blank check company, filed an S-1/A for a $500 million initial public offering to target businesses in the pharmaceutical industry.
NASDAQ
Drugs Made In America Acquisition II Corp. launches a $500 million initial public offering to target pharmaceutical companies, emphasizing domestic supply chain resilience.
NASDAQ
Drugs Made In America Acquisition II Corp., a blank check company, filed an amended S-1 registration statement for a $500 million initial public offering to target the pharmaceutical industry.
NASDAQ
Drugs Made In America Acquisition II Corp. files S-1 for a $500 million initial public offering to target pharmaceutical industry businesses.